
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK,Feb. 13,2025-- Accropeutics Inc. (Accropeutics),a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell deat